Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) traded down 3.4% during mid-day trading on Monday. The company traded as low as $24.86 and last traded at $25.65. 401,641 shares changed hands during trading, an increase of 702% from the average daily volume of 50,104 shares. The stock had previously closed at $26.55.
Neoleukin Therapeutics Stock Performance
The firm’s fifty day moving average is $34.67 and its 200 day moving average is $30.75. The firm has a market cap of $239.18 million, a P/E ratio of -8.18 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc was a biotechnology company focused on developing computationally designed immunotherapies for cancer and other serious diseases. The company used protein-engineering and computational-design technologies to create novel cytokine-based medicines intended to activate the immune system against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines.
Neoleukin’s lead investigational product was NL-201, a designed cytokine mimetic intended to selectively stimulate signaling pathways associated with interleukin-2 and interleukin-15.
Further Reading
- Five stocks we like better than Neoleukin Therapeutics
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
